JAMA Openissa julkaistiin lääkeyhtiö Amgenin rahoittama tutkimus, joka päätyi siihen, että määrätyt statiinit pitää ottaa ja että statiiniannostuksia pitäisi nostaa.
Tutkimuksen tekijöiden taloudelliset sidonnaisuudet lääkeyhtiöihin:
Lainaa:
The conflicts of interest declared by the authors were as follows:
“Conflict of Interest Disclosures: Dr Khunti reported receiving personal fees from Amgen, AstraZeneca, Bayer, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Sanofi, and Servier; reported receiving grants from AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi, and Roche; reported serving as a consultant for Novartis, Novo Nordisk, Sanofi, Lilly, AstraZeneca, Servier, Merck Sharp & Dohme, Boehringer Ingelheim, Amgen, Bayer, and Abbot; and reported serving as a speaker for Novartis, Novo Nordisk, Sanofi, Lilly, AstraZeneca, Merck Sharp & Dohme, and Boehringer Ingelheim. Dr Danese reported receiving grants from Amgen. Dr Kutikova reported owning Amgen stock. Dr Catterick reported owning Amgen stock. Dr Sorio-Vilela reported owning Amgen stock. Dr Gleeson reported receiving grants from Amgen. Dr Kondapally Seshasai reported receiving personal fees from Amgen, reported serving as a consultant for Amgen, and reported receiving grants from Kowa and Sanofi. Dr Brownrigg reported receiving personal fees from Amgen and reported serving as a consultant for Amgen. Dr Ray reported receiving personal fees from lectures from Amgen, Sanofi, Regeneron, Medicines Company, Kowa, Cipla, Algorithm, Boehringer Ingelheim, Novo Nordisk, Takeda, and Astra Zeneca; reported serving as a consultant for Amgen, Sanofi, Regeneron, Medicines Company, Cerenis, Lilly, Ionis Pharma, Akcea, Esperion, and AbbVie; and reported receiving grants from Sanofi, Regeneron, Amgen, Merck Sharpe & Dohme, and Pfizer through his institution.”
Halutut otsikot saatiin mediaan. Tähän tyyliin:
Higher statin doses could stop thousands of heart disease deathsTulokseen päädyttiin monenlaisten huijaustemppujen kautta. Zoe Harcombe paljastaa ne kaikki:
http://www.zoeharcombe.com/2018/12/statins/Mitä tutkimuksesta jää käteen?
Lainaa:
The press release should have said “Study confirms cardiovascular event rate is highest soon after a cardiovascular event.” If you get through year one without an event, the future is far rosier whether you take meds or not, and at whatever dose you take or not. But then, we knew that already.
Rekisteröidy
Kirjaudu sisään
UKK
Etsi
Normaalipainoisena 2013 alkaen enemmän tai vähemmän ketoosissa, karnivori tammikuusta 2018 alkaen 